Clear Search

Showing 7 results for “Lupus nephritis” published 2022.

November 2022

Safety and Efficacy of Belimumab in Patients with Lupus Nephritis

Clin J Am Soc Nephrol. 2022;17:1620–1630 doi: 10.2215/CJN.02520322

This 28-week, open-label extension of BLISS-LN found no new safety signals and maintained efficacy with belimumab, in patients with lupus nephritis.

more…

July 2022
May 2022

Impact of belimumab on organ damage in systemic lupus erythematosus

Arthritis Care Res (Hoboken). 2022 Epub ahead of print doi: 10.1002/acr.24901

Review of clinical trial and real-world data on the effects of belimumab on organ damage in adult patients with SLE shows that belimumab reduces key drivers of organ damage, decreases organ damage progression and, in those with lupus nephritis (LN), decreases renal-related events.

more…

High Systemic Type I Interferon Activity Is Associated with Active Class III/IV Lupus Nephritis

The Journal of Rheumatology 2022; 49:388–97 DOI 10.3899/jrheum.210391

Iwamoto, et al. aimed to determine the association of serum IFN activity with subtypes of lupus nephritis. This study suggests that systemic high type I IFN in SLE is involved in the pathogenesis of severe class III/IV LN and contributes to severe kidney involvement in European-American patients with SLE. However, this effect was independent of anti‑dsDNA antibody status and complement levels. Expression of type I IFN was not found to be clearly related to plasmacytoid dendritic cell infiltration, although it did directly stimulate podocytes to induce chemokines and molecules related to podocyte injury.

more…

March 2022

Long-Term Results of Triple Immunosuppression With Tacrolimus Added to Mycophenolate and Corticosteroids in the Treatment of Lupus Nephritis

Kidney Int Rep. 2021;7(3):516–25

Analysis of 22 patients with lupus nephritis (LN) demonstrates that triple immunosuppression with the addition of tacrolimus to mycophenolate and prednisolone results in further proteinuria reduction.

more…

Phase II randomised trial of type I interferon inhibitor anifrolumab in patients with active lupus nephritis

Ann Rheum Dis. 2022;81(4):496–506 doi: 10.1136/annrheumdis-2021-221478

Despite not meeting the primary endpoint, this Phase II trial of anifrolumab in patients with active lupus nephritis (LN) demonstrates that anifrolumab IR is associated with numerical improvements over placebo across endpoints – including complete renal response – in patients with active LN.

more…